{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:42Z","timestamp":1794255882820,"version":"4.9.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03738-6","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:57:38Z","timestamp":1787302658000},"page":"5581-5598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperkalemia Management in the US Cohort of the Prospective, Observational, Real-World TRACK Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Elvira O.","family":"Gosmanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna P.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Kathresal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wittbrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"7","key":"3738_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00392-008-0668-3","volume":"97","author":"C Werner","year":"2008","unstructured":"Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7):418\u201331. https:\/\/doi.org\/10.1007\/s00392-008-0668-3.","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"3738_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341. https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.011.","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"3738_CR3","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"36","key":"3738_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"12","key":"3738_CR5","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s10157-025-02728-2","volume":"29","author":"T Fujimaru","year":"2025","unstructured":"Fujimaru T, Hirose K, Yazawa M, et al. Management of hyperkalemia: strategic clinical actions in real-world practice. Clin Exp Nephrol. 2025;29(12):1699\u2013711. https:\/\/doi.org\/10.1007\/s10157-025-02728-2.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"3738_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/03007995.2020.1775072","volume":"36","author":"F Mu","year":"2020","unstructured":"Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020;36(8):1333\u201341. https:\/\/doi.org\/10.1080\/03007995.2020.1775072.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"3738_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ckj\/sfab243","volume":"15","author":"T Humphrey","year":"2022","unstructured":"Humphrey T, Davids MR, Chothia MY, et al. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2022;15(4):727\u201337. https:\/\/doi.org\/10.1093\/ckj\/sfab243.","journal-title":"Clin Kidney J"},{"issue":"3S","key":"3738_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1\u201387. https:\/\/doi.org\/10.1016\/j.kint.2020.11.003.","journal-title":"Kidney Int"},{"issue":"1","key":"3738_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E, Rastogi A, Murohara T, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24(1):18. https:\/\/doi.org\/10.1186\/s12882-022-03054-5.","journal-title":"BMC Nephrol"},{"issue":"2","key":"3738_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-related discontinuation of renin\u2013angiotensin\u2013aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022;80(2):164-73.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.01.002.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3738_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae295","volume":"17","author":"J Hsia","year":"2024","unstructured":"Hsia J, Shivappa N, Bakhai A, et al. Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making. Clin Kidney J. 2024;17(10):sfae295. https:\/\/doi.org\/10.1093\/ckj\/sfae295.","journal-title":"Clin Kidney J"},{"key":"3738_CR12","doi-asserted-by":"publisher","unstructured":"Ferraro PM, Shivappa N, Bakhai A, et al. Treatment strategies in incident and recurrent hyperkalemia: insights from the TRACK study. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03666-5.","DOI":"10.1007\/s12325-026-03666-5"},{"issue":"7","key":"3738_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.healthpol.2019.05.001","volume":"123","author":"N Reibling","year":"2019","unstructured":"Reibling N, Ariaans M, Wendt C. Worlds of healthcare: a healthcare system typology of OECD countries. Health Policy. 2019;123(7):611\u201320. https:\/\/doi.org\/10.1016\/j.healthpol.2019.05.001.","journal-title":"Health Policy"},{"key":"3738_CR14","unstructured":"Paris: Organisation for Economic Co-operation and Development. Health systems institutional characteristics: a survey of 29 OECD countries. Health Working Paper 50. 2010. https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2010\/04\/health-systems-institutional-characteristics_g17a1e51\/5kmfxfq9qbnr-en.pdf. Accessed 10 Jul 2026."},{"issue":"2","key":"3738_CR15","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.kisu.2021.01.010","volume":"11","author":"AK Bello","year":"2011","unstructured":"Bello AK, Okpechi I, Jha V, et al. Understanding distribution and variability in care organization and services for the management of kidney care across world regions. Kidney Int Suppl. 2011;11(2):e4\u201310. https:\/\/doi.org\/10.1016\/j.kisu.2021.01.010.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"3738_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.kisu.2023.12.002","volume":"13","author":"I Okpechi","year":"2024","unstructured":"Okpechi I, Bello A, Levin A, Johnson D. Update on variability in organization and structures of kidney care across world regions. Kidney Int Suppl (2011). 2024;13(1):6\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2023.12.002.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"7","key":"3738_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jch.13563","volume":"21","author":"R Pecoits-Filho","year":"2019","unstructured":"Pecoits-Filho R, Fliser D, Tu C, et al. Prescription of renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J Clin Hypertens (Greenwich). 2019;21(7):991\u20131001.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"3738_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","volume":"6","author":"B Stengel","year":"2021","unstructured":"Stengel B, Muenz D, Tu C, et al. Adherence to the kidney disease: improving global outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep. 2021;6(2):437\u201348. https:\/\/doi.org\/10.1016\/j.ekir.2020.11.039.","journal-title":"Kidney Int Rep"},{"key":"3738_CR19","unstructured":"FACIT. Functional assessment of chronic illness therapy\u2014Treatment satisfaction\u2014General. https:\/\/www.facit.org\/measures\/facit-ts-g. Accessed 13 Jan 2026."},{"issue":"7","key":"3738_CR20","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s12325-025-03228-1","volume":"42","author":"C Wanner","year":"2025","unstructured":"Wanner C, Zhao MH, Amin AN, et al. Guideline-recommended disease-modifying therapies for patients with cardiorenal disease: a call-to-action narrative review. Adv Ther. 2025;42(7):3141\u201357. https:\/\/doi.org\/10.1007\/s12325-025-03228-1.","journal-title":"Adv Ther"},{"issue":"3","key":"3738_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","volume":"96","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744\u201362. https:\/\/doi.org\/10.1016\/j.mayocp.2020.06.014.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"3738_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1053\/j.akdh.2024.08.003","volume":"31","author":"A Rastogi","year":"2024","unstructured":"Rastogi A, Chertow GM, Collins A, et al. Utilization of potassium binders for the management of hyperkalemia in chronic kidney disease: a position statement by US nephrologists. Adv Kidney Dis Health. 2024;31(6):514\u201322. https:\/\/doi.org\/10.1053\/j.akdh.2024.08.003.","journal-title":"Adv Kidney Dis Health"},{"issue":"1","key":"3738_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001570","volume":"3","author":"C Doyle","year":"2013","unstructured":"Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570. https:\/\/doi.org\/10.1136\/bmjopen-2012-001570.","journal-title":"BMJ Open"},{"issue":"8","key":"3738_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","volume":"47","author":"KB Zolnierek","year":"2009","unstructured":"Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826\u201334. https:\/\/doi.org\/10.1097\/MLR.0b013e31819a5acc.","journal-title":"Med Care"},{"issue":"5","key":"3738_CR25","doi-asserted-by":"publisher","first-page":"e2314211","DOI":"10.1001\/jamanetworkopen.2023.14211","volume":"6","author":"SB Dusetzina","year":"2022","unstructured":"Dusetzina SB, Besaw RJ, Whitmore CC, et al. Cost-related medication nonadherence and desire for medication cost information among adults aged 65\u00a0years and older in the US in 2022. JAMA Netw Open. 2022;6(5):e2314211. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14211.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3738_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/imj.16370","volume":"54","author":"N Ghinea","year":"2024","unstructured":"Ghinea N. The increasing costs of medicines and their implications for patients, physicians and the health system. Intern Med J. 2024;54(4):545\u201350. https:\/\/doi.org\/10.1111\/imj.16370.","journal-title":"Intern Med J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03738-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:35Z","timestamp":1794254615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3738"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03738-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elvira O. Gosmanova is an employee of the US Department of Veterans Affairs. Opinions expressed in this paper are those of the authors and do not necessarily represent the opinion of the Department of Veterans Affairs. Elvira O. Gosmanova reported receiving honoraria from Ascendis Pharma, CSL Vifor, and AstraZeneca\/Alexion, and institutional research support from AstraZeneca\/Alexion and CSL Behring. Javed Butler reported receiving consulting fees from\u00a0Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Eli Lilly, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Mankind, Medtronic, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, PharmaIN, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, RyCarma, Saillent, Salamandra, Salubris, SC Pharma, Secretome, Sequana, SQ Innovation, Transmural, TikkunLev, Tenex, Tricog, Ultromics, Vera, and Zoll. Johanna P. Contreras reported receiving grant support from Novo Nordisk and Cytokinetics, and consulting fees from Boehringer Ingelheim and AstraZeneca. Linda F. Fried is a member of Data Monitoring Committees for Regeneron and Novo Nordisk. Amarnath Kathresal declares no conflicts of interest. Wolfgang C. Winkelmayer reported receiving consulting fees from Akebia, Anthos, Apellis, AstraZeneca, Bayer, Boehringer Ingelheim, Cadrenal, City, Idorsia, Merck, Natera, Novartis, and Vera. Hungta Chen, Pooja Desai, Mark Sanford, and Eric Wittbrodt are employees of, and may hold stock in, AstraZeneca. Judith Hsia owns AstraZeneca stock and receives salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that has received research grant\/consulting funding from AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TRACK study was approved by central and local institutional review boards\/independent ethics committees (Supplementary Table\u00a0\n                      \n                      ) and all participants provided informed consent. The study was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki, the\u00a0International Council for Harmonisation Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices, Good Pharmacoepidemiology Practices, and applicable legislation for observational studies.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}